News

Press Release 2020.08.25

Interim Progress in the Development of Treatment for COVID-19

Bonac Corporation reports the progress of research and development of a therapeutic agent for COVID-19, which is being conducted in collaboration with the Fukuoka Institute of Health and Environmental Sciences.

 

Since the start of the joint research, Bonac has designed and synthesized a nucleic acid medicine candidate, and cell-based assays have confirmed its effectiveness in significantly inhibiting the growth of SARS-CoV-2. As a result, it was confirmed that the drug is effective in suppressing the multiplication of the virus.

 

In addition, since the efficacy against the SARS-CoV-2 was confirmed, the drug will be used to treat MERS (Middle East Respiratory Syndrome) and SARS (Severe Acute Respiratory Syndrome), which are also infectious diseases caused by coronaviruses and for which there is currently no cure.

 

Bonac will continue to promote research and development so that the nucleic acid chemistry technology will serve as a bridge to drug discovery.

 

Contact:

Corporate Affairs

press@bonac.co.jp

Interim Progress in the Development of Treatment for COVID-19

Back to News List

  • Interim Progress in the Development of Treatment for COVID-19

ページ上部へ